Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

MLA

Paul W. Jones, et al. Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. Nov. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0dc8c006cdfc9da6d4a8e2db383f6f79&authtype=sso&custid=ns315887.

APA

Paul W. Jones, Alan Martin, Isabelle Boucot, David A. Lipson, Edward Kerwin, Dhvani Shah, Afisi S. Ismaila, Robyn Kendall, François Maltais, Chris Compton, Leif Bjermer, Nancy Risebrough, Lee Tombs, Claus Vogelmeier, & Soham Shukla. (2021). Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.

Chicago

Paul W. Jones, Alan Martin, Isabelle Boucot, David A. Lipson, Edward Kerwin, Dhvani Shah, Afisi S. Ismaila, et al. 2021. “Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0dc8c006cdfc9da6d4a8e2db383f6f79&authtype=sso&custid=ns315887.